Impact of Tiotropium Add-on Therapy in Patients With Asthma

Boehringer Ingelheim

Status

Completed

Conditions

Asthma

Treatments

Drug: Inhaled Corticosteroid/Long-acting beta-agonist

Drug: Tiotropium Respimat®

Study type

Observational

Funder types

Industry

Identifiers

NCT03964220

0205-0543

Details and patient eligibility

About

To evaluate the effectiveness of add on therapy with Tiotropium Respimat® compared to increasing the dose of ICS in patients with a diagnosis of Asthma and on ICS/LABA therapy

Enrollment

7,857 patients

Sex

All

Ages

12+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with least one asthma diagnosis in the inpatient setting or at least two separate instances of asthma diagnosis (separated by at least 30 days) recorded in the outpatient or emergency room setting will be included.
Patients will be required to be already on Inhaled Corticosteroid/Long-acting beta-agonist (ICS/LABA).
Patients will be required to have available records 12 months prior to the index date.

Exclusion criteria

Patients below the age of 6 years on the Inhaled Corticosteroid/Long-acting beta-agonist initiation (ICS/LABAi) date will be excluded.
Patients with a diagnosis of COPD at any time during the study period will be excluded.
Those who are on biologics at baseline will be removed.
After the PSM process, unmatched patients will be excluded.